Aquestive Therapeutics, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2021-03-12

Reporting Person: BRATTON DOUGLAS K (N/A)
Reporting Person: MonoLine Partners, L.P. (N/A)
Reporting Person: MonoLine RX, L.P. (N/A)
Reporting Person: MonoLine RX II, L.P. (N/A)
Reporting Person: MonoLine RX III, L.P. (N/A)
Reporting Person: MonoSol Rx Genpar, L.P. (N/A)
Reporting Person: MRX Partners, LLC (N/A)
Reporting Person: Bratton Capital Inc. (N/A)
Reporting Person: Bratton Capital Management, L.P. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-12	Common Stock	J	524675	—	Disposed	1688639	Indirect
2021-03-12	Common Stock	J	564160	—	Disposed	3468747	Indirect
2021-03-12	Common Stock	J	97598	—	Disposed	2657943	Indirect
2021-03-12	Common Stock	J	40404	—	Disposed	47051	Indirect
2021-03-12	Common Stock	J	2249077	—	Disposed	0	Indirect
2021-03-12	Common Stock	J	1783578	—	Acquired	1948578	Indirect
2021-03-09	Common Stock	G	62500	—	Disposed	12585	Direct

Footnotes

F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F4: These securities are beneficially owned by Monoline Rx.

F5: These securities are beneficially owned by Monoline II.

F6: These securities are beneficially owned by Monoline III.

F7: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol.

F8: These securities are beneficially owned by MRX Partners.

F9: Shares of Common Stock acquired through pro rata distribution for no consideration by MRX Partners.

F10: These securities are beneficially owned by MonoLine.

F11: Gift of shares of Common Stock to charitable organization.

F12: Following the transactions reported on this Form 4, the Reporting Persons as listed in this Form 4 are the beneficial owners in the aggregate of 10,060,657 shares of Common Stock for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, representing a 27.8% ownership interest in the Issuer based on total shares outstanding of 36,213,969 as of March 5, 2021, such shares outstanding as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.